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Background: Increased levels of markers of systemic inflammation have been associated with serious non-AIDS
events even in patients on fully suppressive antiretroviral therapy. We explored residual viremia and systemic
inflammation markers in patients effectively treated with ritonavir-boosted protease inhibitor monotherapy (PImono).
Methods: HIV-infected adults with persistent HIV-RNA <50 copies/ml and treated with either a) PImono or b) standard
triple-drug cART were recruited for this cross-sectional, exploratory study. Plasma samples were tested for high-sensitivity
CRP (hsCRP), Serum Amyloid A (SAA), soluble CD14, IL-6, IL-8 and Cytochrome C. HIV-RNA was measured by real-time
PCR (detection limit of 10 copies/ml).
Results: 81 patients were recruited (31% on PImono). Two out of 25 (8%) and 3 of 56 (5.4%) patients from the PImono
and cART groups respectively had detectable HIV-RNA. Significant correlation between SAA and hsCRP was observed
(0.804). No difference between groups was found on prevalence of hsCRP >3 mg/l (21% vs 20% in the PImono and
cART groups respectively; p = 0.577) or SAA >6.4 mg/l (38% vs 22% in the PImono and cART groups respectively;
P = 0.172). In a univariate analysis IL6 and IL8 levels were associated with SAA >6.4 mg/l (OR = 1.74 and 1.46; 95%
CI = 1.00 – 3.03 and 1.06 – 2.01; p = 0.051 and 0.02 respectively) and hsCRP >3 mg/l in (OR = 2.00 and 1.37; 95%
CI = 1.09 – 3.69 and 1.02 – 1.85; p = 0.026 and 0.039 respectively).
Conclusions: We found no evidence of increased levels of inflammatory biomarkers or higher prevalence of residual
viraemia in patients effectively suppressed on PImono as compared with patients on standard cART.
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Persistent systemic inflammation has been associated with
an increased risk of serious non-AIDS defining events,
such as cardiovascular disease (CVD), in HIV-positive
adults despite effective treatment with antiretroviral ther-
apy (ART) [1,2]. Standard ART regimens usually include
three different drugs from at least two drug classes. How-
ever, ART simplification strategies have been proposed to
reduce long-term toxicity, cost and possible pharmacokinetic* Correspondence: A.Arenas-Pinto@ucl.ac.uk
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unless otherwise stated.interactions, particularly in an aging population that is
likely to be prescribed multiple medications [3].
Protease inhibitor monotherapy (PImono) has been ex-
plored as treatment simplification strategy in a number of
randomised clinical trials [4-6]. However, in clinical prac-
tice it seems like patients on PImono show a viral load re-
bound rate higher than what would be expected in
combination ART (cART) treated patients and this has
been suggested to be due to persistent residual viraemia
below the detection limit of currently used assays [5]. In-
creased levels of systemic inflammation markers have been
reported in patients with HIV low-level viraemia and have
been associated with a number of serious non-AIDS defin-
ing complications. High-sensitivity C-reactive protein
(hsCRP) and Interleukins 6 and 10 (IL-6, IL-10) have been
reported as predictors of serious non-AIDS definingentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Serum Amyloid A (SAA) is a lipoprotein secreted during
the acute phase of inflammation which has been consid-
ered more sensitive than CRP in some rheumatologic con-
ditions, although the magnitude of increase is often be
greater than that of CRP [10,11]. In acute viral infections
SAA levels appear to increase more than CRP [12,13].
We have performed a cross-sectional, exploratory study
comparing residual viraemia and systemic inflammatory
markers in patients free of major co-morbidities and ef-
fectively suppressed on either standard cART or PI mono-
therapy. We also aimed to explore the level of




HIV-positive adults on ART for at least 48 weeks and with
documented HIV-RNA <50 copies/ml for at least
24 weeks, and no change in their ART over the same
period immediately prior to enrolment were recruited for
this cross-sectional study at a single site in London. At en-
rolment, patients were taking either a) a ritonavir-boosted
protease inhibitor as a single agent (PImono) or b) cART
comprising two NRTI and a third anti-retroviral agent and
should have had ≥200 CD4 cell/mm3. Because the study
aimed to investigate markers of systemic inflammation
and immune activation in patients free of major co-
morbidities likely to impact on these, patients were con-
sidered not eligible if they had a previous history of any
autoimmune disease (e.g. systemic lupus erythematous,
Addison’s disease, Graves’ disease, multiple sclerosis, my-
asthenia gravis, rheumatic and reactive arthritis, etc.),
CVD (defined as previous myocardial infraction, stroke or
coronary revascularisation), treatment for any acute op-
portunistic infection within three months prior to enrol-
ment, any serious bacterial infection (e.g. pneumonia,
meningitis, septicaemia, etc.) in the two months prior to
enrolment, any acute infection with fever and systemic
symptoms within the last 72 hours before enrolment, any
vaccination in the two months prior to enrolment or if
they had used systemic corticosteroids or any other
immune-modulatory drug within the 12 months prior to
enrolment. Patients who were hepatitis B surface antigen
(HBsAg) or hepatitis C RNA positive were also excluded.
Clinical and epidemiological data, including demograph-
ics, date of first HIV antibody positive result, ART history
and relevant past medical history was obtained from par-
ticipants medical records.
Informed consent was obtained from all study partici-
pants. The study was reviewed by the National Ethics
Research Service Committee London – Queen’s Square
(Ref. 11/LO/1102) and the North Central London Re-
search Consortium R&D Office.Biomarkers
Plasma samples were tested for hsCRP (COBAS MIRA;
Roche Diagnostics GmbH), SAA (BNII auto-analizer;
Dade Behring, Marburg, Germany), sCD14, ILs1b, 6, 8,
10 and 12p70, and TNF-α (BD Biosciences CBA, San
Jose, CA, USA) and Cytochrome C (R&D Quantikine,
MN, USA). HIV-RNA was measured by real-time PCR
with a detection limit of 10 copies/ml (in-house devel-
oped assay by UCLH virology department; CPA accre-
dited). Samples were stored at −80°C and tested at the
end of the study period in a single batch.
Statistical analysis
Continuous data were summarised and compared using
the Mann-Witney test or grouped into categories where
Fischer’s exact test was used. Significance level set as
p < 0.05 in all analyses. Clinically significant elevation of
hsCRP and SAA were defined as >3 and 6.4 mg/l re-
spectively. Simple linear regression was used to explore
correlation between hsCRP and SAA levels. Associations
with elevated hsCRP and SAA were explored using lo-
gistic regression.
Results
A total of 81 treated HIV-infected patients were recruited
of whom, 25 (31%) were being treated with PImono. Most
of patients on cART were receiving abacavir-containing
(96%) and PI-based (57%) combinations. Patients on
PImono were mainly receiving DRV/RTV (80%) (Table 1).
Median age was 46.2 years (Inter quartile range (IQR)
42.2 – 52.7) and there was no difference between study
groups on age distribution. There were more female pa-
tients in the cART group (26.8%) compared to the PImono
group (4%; p = 0.017). Patients on cART were known with
HIV infection for slightly longer (median 11.8; IQR = 8.2-
16.7 years) than patients on PImono (median 9.6; IQR =
7.3- 14.3 years) (p = 0.091). Median CD4 count was similar
between study groups (550 cell/ml; IQR = 460-740 and
615 cell/ml; IQR = 470-770 for the PImono and the cART
groups respectively; p = 0.210). All study participants had
HIV-RNA <50 copies/ml at entry. Two out of 25 (8%) and
3 of 56 (5.4%) patients from the PImono and cART groups
respectively had residual viraemia (i.e. HIV-RNA 10–50
copies/ml) (p = 0.648). Two of the patients with detectable
viraemia were being treated with ritonavir-boosted daru-
navir monotherapy whereas the other three were on aba-
cavir, lamivudine and either efavirenz or nevirapine.
There was no difference in the distribution of hsCRP
and SAA levels between the study groups (Table 2). Over-
all, 20% of participants had hsCRP >3 mg/l, but no differ-
ence between groups was found (21% vs 20% in the
PImono and cART groups respectively; p = 0.577). Simi-
larly, there was no difference between groups in the pro-
portion of participants with SAA >6.4 mg/l (upper limit of
Table 1 Patients characteristics
PI Monotherapy (N = 25) cART (N = 56) P1
N % N %
Female sex 1 4.0 15 26.8 0.017
Detectable HIV-RNA2 2 8.0 3 5.4 0.648
hsCRP >3 mg/l 5 20.8 11 20.0 0.577
SAA >6.4 mg/l 9 37.5 12 21.82 0.172
IL6 > 3 pg/ml 1 4.8 1 1.9 0.490
PI exposure 25 100.0 32 57.0
ATV/RTV 3 12.0 16 28.6
DRV/RTV 20 80.0 9 16.1
LPV/RTV 2 8.0 4 7.1
Other PI 0 0.0 3 5.4
NNRTI exposure 23 41.1
EFV 11 19.6
NVP 12 21.4
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groups respectively; p = 0.172). We found no difference on
the proportion of patients with elevated hsCRP or SAA
between patients on PImono or NNRTI-based cART (p =
0.702 and 0.096 respectively). Other markers of inflamma-
tion and mitochondrial function did not differ between
groups as shown in Table 2.
A significant correlation between SAA and hsCRP was
observed (0.804) with a regression coefficient of 3.507 (95%
CI 2.92-4.20; p < 0.001) suggesting an expected increment
of 3 mg/l in SAA for each unit increment in hsCRP. A total
of 14 participants had hsCRP >3 mg/l and SAA >6.4 mg/l,
whereas seven of the 21 patients with SAA >6.4 mg/l
(33%) had hsCRP <3 mg/l. In a logistic regression analysis
IL6 and IL8 levels were associated with SAA >6.4 mg/l
(OR = 1.74 and 1.46; 95% CI 1.00-3.03 and 1.06-2.01;
p = 0.051 and 0.02 respectively) whereas younger age andTable 2 Systemic inflammation and mitochondrial dysfunctio
PI Monotherapy (N = 25) cART
Median IQR Medi
hsCRP (mg/l) 0.85 0.54 - 2.135 0.96
SAA (mg/l) 1.8 1.35 - 9.3 3.5
IL-6 pg/ml 1.51 1.28 - 2.95 1.41
IL-8 pg/ml 2.39 1.84 - 3.9 2.56
Cytochrome C (ng/dl) 3.444 2.596 - 4.449 3.349
sCD14 (ng/dl) 1.744 1.575 - 2.071 1.758
*Mann–Whitney test.female gender showed an inverse association with SAA
>6.4 mg/l (OR = 0.94 and 0.37; 95% CI 0.88-1.00 and 0.12-
1.16 respectively). In a multivariate model only age
remained independently associated with SAA >6.4 mg/l
(OR = 0.92; 95% CI 0.86-0.99; p = 0.038). IL6 and IL8 levels
were also associated with hsCRP >3 mg/l in univariate ana-
lysis (OR = 2.00 and 1.37; 95% CI 1.09-3.69 and 1.02-1.85;
p = 0.026 and 0.039 respectively).
Discussion
We did not find any evidence of increased levels of inflam-
matory biomarkers or higher prevalence of residual vir-
aemia in patients with HIV viral loads <50 copies/ml while
treated with PImono as compared with patients on cART
which is consistent with previous studies where PI mono-
therapy has been compared to PI-based cART [14,15].
However, Torres et al. have reported higher monocyte acti-
vation, inflammation and residual viraemia in patients on
PI monotherapy compared to PI-based cART [16]. In our
study the majority of subjects showed low plasma levels of
hsCRP and SAA as expected in well suppressed patients
with no major co-morbidities. However, the levels of CRP
and IL6 reported in previous studies with less stringent ex-
clusion criteria were much higher and the proportion of
participants with known co-morbidities such as hepatitis C
was about 20% [15,16]. Increased monocyte activation, sys-
temic inflammation and immune activation markers have
all been associated with a number of inflammatory conditions,
including HCV infection [17], and some of these could have
been contributed to partially explain controversial results.
Residual viraemia has been observed more frequently in
patients on PI-based compared to NNRTI-based cART
[18]. However, in our study 40% of the control group were
on NNRT-base cART and we still found no difference in
residual viraemia between groups. In randomised trials PI
monotherapy has been associated with a higher viral load
rebound rate compared to cART but ours and previous re-
sults appear to suggest that persistent residual viraemia
may not be the mechanism for viral load rebounds in pa-
tients treated with PI as single agent [4-6].
Because the detection limit of the PCR assay we used,
we cannot exclude the possibility of differences in veryn markers
(N = 56) P* Overall (N = 81)
an IQR Median IQR
0.56 - 2.44 0.798 0.93 0.56 - 2.41
1.8 - 3.5 0.462 3.1 1.6 - 6.8
1.21 - 1.86 0.675 1.45 1.24 - 1.87
1.94 - 3.34 0.792 2.54 1.92 - 3.48
2.11 - 4.593 0.575 3.444 2.219 - 4.59
1.5 - 2.289 0.783 1.744 1.511 - 2.147
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but if there was any, that does not appeared to have any
impact on systemic inflammation. However, we found
that 26% of the study population had SAA levels
>6.4 mg/l, which are considered elevated, and have been
associated with active inflammatory conditions [19]. Fur-
thermore, clinically significant elevations in SAA were
associated with IL-6 and IL-8 levels and these have been
previously reported to be associated with serious non-
AIDS events [20]. Further investigation of SAA as a
marker of systemic inflammation in HIV-infected popu-
lations may be of interest.
Mitochondrial dysfunction may lead to systemic in-
flammation and has been reported as an important
mechanism in acute response to trauma [21]. NRTIs can
induce mitochondrial dysfunction and this could be a
mechanism to trigger an inflammatory response locally
or systemically. Cytochrome-C (Cyt-C) is a marker of
mitochondrial function and integrity and has been asso-
ciated with inflammation and apoptosis [22] but, in our
study, plasma levels of Cyt-C were not different between
groups. Most of participants in the cART group (96%)
were taking abacavir-based ART which is less likely to
cause mitochondrial impairment than other NRTI
although it has been associated with an excess risk for
cardiovascular events [23,24].
Our study has limitations related to the study design
and the small size of the study population. In addition,
the study population included a selected group of pa-
tients and treatment allocation was not randomised.
However, we believe ours is the first study looking at the
question of systemic inflammation and low-level
viraemia in patients on PI monotherapy compared to
PI and NNRTI-based cART in a population free of ser-
ious co-morbidities, meaning that the effect of any con-
comitant morbidity on systemic inflammation can be
ruled out.Conclusions
Our data add further evidence suggesting that patients
with persistent HIV-RNA <50 copies/ml while on PI
monotherapy are not more likely to have increased levels
of systemic inflammation markers circulating in plasma or
residual viraemia than patients on standard cART.
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